Where can Biogen turn after mammoth Alzheimer's blow? The M&A table, analysts say

Biogen’s worst fears have come true with the failure of its phase 3 Alzheimer’s prospect aducanumab. And with one of its key blockbusters under threat, it may be “buy or be bought” time for the Big Biotech.